Single oncogenic driver of glioblastoma: The SRSF3 splicing factor.

Takeaway

  • SRSF3 was directly associated with the development, progression and aggressiveness of glioblastoma and also correlated with patient survival. This gene represents a novel therapeutic target that warrants clinical testing.

Why this matters

  • There is emerging data that indicate gene splicing mechanisms are altered in tumors, which lead to oncogenic splicing events associated with the progression and aggressiveness of tumors.

  • The results from this study provide valuable insights of the splicing machinery in glioblastomas and to developing novel strategies to support the diagnosis, prognosis and treatment of glioblastomas.